Dr. Shuihua Lu: Trends in PAN-TB Treatment and Mid-term Report Review on QDB Study丨CROI Commentary

Dr. Shuihua Lu: Trends in PAN-TB Treatment and Mid-term Report Review on QDB Study丨CROI Commentary

In recent years, the concept of PAN-TB treatment, representing a comprehensive approach to tuberculosis (TB) therapy, has seen numerous developmental breakthroughs. This universal treatment method is applicable to all types of TB patients and is not limited by the resistance of traditional anti-tuberculosis drugs (i.e., there's no need to test for drug resistance), offering advantages such as simplified treatment and shortened course duration. At the recently concluded 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024), a Phase 2b/c study (Abstract No: 163) presented in the form of a late-breaking abstract was selected for oral presentation. This study explored the efficacy and safety of a 4-month regimen of Quabodepistat, Delamanid, and Bedaquiline in treating pulmonary TB. Infectious Disease Frontier has invited Dr.
Dr. Hui Wang: Long-acting Cabotegravir Maintains High Efficacy in Preventing HIV Among Populations with High Incidence of Bacterial STIs丨CROI Commentary

Dr. Hui Wang: Long-acting Cabotegravir Maintains High Efficacy in Preventing HIV Among Populations with High Incidence of Bacterial STIs丨CROI Commentary

The association between sexually transmitted infections (STIs) and HIV infection has always been a focal point in the medical community. With the promotion of pre-exposure prophylaxis (PrEP) strategies to prevent HIV infection, the impact of STIs on the effectiveness of PrEP has become an urgent issue to address. At the recently concluded Conference on Retroviruses and Opportunistic Infections (CROI 2024), researchers presented an oral abstract (Abstract 131) that explored the relationship between STI status and the effectiveness of two PrEP regimens (CAB-LA and daily oral TDF/FTC). Infectious Disease Frontier invited Dr. Hui Wang from The Third People's Hospital of Shenzhen to provide an in-depth commentary on this study.
Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature

Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature

In December 2023, professor Erlie Jiang and  team from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published an influential study in Frontiers in Immunology, detailing the challenges of managing refractory cytomegalovirus (CMV) infections in Chinese patients after allogeneic hematopoietic cell transplantation (allo-HCT). With a focus on China's unique position in the global context of allo-HCT and the specific difficulties faced by patients with haploidentical donors, this review underscores the urgent need for standardized care protocols. Jiang's work, through its comprehensive analysis of existing literature, significantly advances our understanding of CMV management post-transplant, aiming to improve patient outcomes and establish effective treatment guidelines. This study marks a critical step forward in optimizing post-transplant care to enhance patient survival and quality of life amidst CMV infection challenges.

Website Disclaimer

Content marked as original on the "Infectious Disease Frontier" platform holds copyright under Infectious Disease Frontier. While we encourage sharing and reproduction of our content, it must be done with prior written consent from Infectious Disease Frontier. Unauthorized use is strictly prohibited, and legal action may be taken against infringement.
Advancements in Predicting Patient Outcomes: A Multidimensional Approach to COVID-19 with the Omicron Variant

Advancements in Predicting Patient Outcomes: A Multidimensional Approach to COVID-19 with the Omicron Variant

The COVID-19 pandemic, heightened by the emergence of the Omicron variant, has presented substantial challenges in managing patient conditions and predicting outcomes. Researchers at Peking Union Medical College Hospital sought to address this by developing a dynamic prediction model utilizing machine learning techniques. This study aimed to accurately forecast the deterioration or recovery of hospitalized COVID-19 patients, incorporating daily multidimensional data from 995 patients. Employing an ensemble machine learning approach, the researchers utilized the XGBoost algorithm. The resulting models exhibited promising discrimination capabilities, offering a valuable tool for clinicians to assess the likelihood of condition changes in the medium term.
Dr.Taisheng Li: A New Concept in Comprehensive Diagnosis and Treatment in the Post-ART Era of HIV/AIDS

Dr.Taisheng Li: A New Concept in Comprehensive Diagnosis and Treatment in the Post-ART Era of HIV/AIDS

The 15th National Conference on AIDS and Hepatitis C, hosted by the Chinese Medical Association and its Infectious Diseases Branch, took place in Guangzhou from November 10 to 12, 2023. Dr. Taisheng Li, the conference chair and a renowned figure from Peking Union Medical College Hospital, delivered a captivating presentation titled "A New Concept in Comprehensive Diagnosis and Treatment in the Post-ART Era of HIV/AIDS." In an exclusive interview with Infectious Disease Frontline, he further shared insights on topics including immune reconstitution deficiency in HIV-infected individuals.
IAS Hot Review | Professor Wang Hui: Second-line treatment choice for children with HIV infection — CHAPAS-4 clinical trial 96-week data

IAS Hot Review | Professor Wang Hui: Second-line treatment choice for children with HIV infection — CHAPAS-4 clinical trial 96-week data

Currently, the choice of second-line antiretroviral therapy (ART) for children infected with HIV is extremely limited. At the recently concluded 12th International AIDS Society HIV Science Conference (IAS 2023), researchers announced the results of a significant clinical study, the CHAPAS-4 (Conference Abstract No.: OALBB0503), focusing on the long-term treatment outcomes of second-line therapy in children with HIV infections. We specially invited Professor Wang Hui from the Affiliated Second Hospital of Southern University of Science and Technology (Shenzhen Third People's Hospital) to provide a brilliant review of this research.